14 December 2022
RUA Life Sciences Plc
("RUA Life Sciences", the "Company" or the "Group")
Director Dealing
RUA Life Sciences, the holding company of a group of medical device businesses focused on the exploitation of the patented long-term implantable biostable polymer, Elast-EonTM, announces that it was notified on 14 December 2022 that Lachlan Smith, Chief Financial Officer, purchased 19,341 ordinary shares in the Company at 54.2p on 14 December 2022.
Following the purchase, Lachlan Smith owns 19,341 ordinary shares of the Company.
For further information contact:
RUA Life Sciences
Bill Brown, Chairman Tel: +44 (0)1294 317073
Caroline Stretton, Group Managing Director Tel: +44 (0)1294 317073
Cenkos Securities plc (Nominated Adviser and Broker) Tel: +44 (0)20 7397 8900
Giles Balleny / Max Gould (Corporate Finance)
Michael Johnson (Sales)
| 1. | Details of the person discharging managerial responsibilities/person closely associated
| |||||
| a) | Name: | Lachlan Smith via SIPP | ||||
| 2. | Reason for the notification
| |||||
| a) | Position/status: | Chief Financial Officer
| ||||
| b) | Initial notification/Amendment: | Initial notification
| ||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |||||
| a) | Name: | RUA Life Sciences plc | ||||
| b) | LEI: | 213800BMVB22PVOJ9Z28 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |||||
| a) | Description of the financial instrument, type of instrument: Identification code: | Ordinary Shares of 5 pence GB0033360586 | ||||
| b) | Nature of the transaction: | Purchase of Ordinary Shares
| ||||
| c) | Price(s) and volume(s): |
| ||||
| d) | Aggregated information: · Aggregated volume: · Price: |
n/a | ||||
| e) | Date of the transaction: | 14 December 2022
| ||||
| f) | Place of the transaction: | London Stock Exchange
| ||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
